A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Recruiting

Back to Neovascular Age-related Macular Degeneration trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(3 sites)

China

Peking Union Medical College Hospital, Beijing

Eye & ENT Hospital of Fudan University, Shanghai

Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of MedicineXin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

Trial locations(3 sites)

Interested in joining?